Online inquiry

IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5105MR)

This product GTTS-WQ5105MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD52 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001803.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1043
UniProt ID P31358
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5105MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15910MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ8039MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ15470MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ702MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ3995MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ11806MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ8294MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ7513MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GC-1102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW